Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy.
Transplantation and cellular therapy(2022)
Abstract
Mocravimod is safe and the here presented results support a larger study to investigate efficacy in a homogeneous AML patient population undergoing allo-HSCT.
MoreTranslated text
Key words
Mocravimod,Graft-versus-host disease,Graft-versus-leukemia,Allogeneic HSCT,S1PR modulator
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined